P2Y12 Platelet Function Assay for Assessment of Bleeding Risk in Coronary Artery Bypass Grafting
Publication Date
2014
Journal Title
J Card Surg
Abstract
Background The use of platelet function testing has been advocated to individualize the time needed between discontinuation of P2Y12 inhibitors and coronary artery bypass grafting (CABG). However, the use of specific point-of-care assays to predict bleeding risk in patients on P2Y12 inhibitors prior to CABG has not been fully validated. Methods From September 2012 to May 2013, 81 patients on P2Y12 inhibitors underwent isolated CABG. Preoperative level of P2Y12 receptor blockade was measured using the VerifyNow P2Y12 assay. Packed red blood cell (pRBC) and platelet transfusions and postoperative chest tube output were correlated with preoperative P2Y12 reaction units (PRUs). Results Patients who stopped P2Y12 inhibitors for
Volume Number
29
Issue Number
3
Pages
312-316
Document Type
Article
EPub Date
2014/03/05
Status
Faculty, Northwell Researcher
Facility
School of Medicine; Northwell Health
Primary Department
Cardiovascular and Thoracic Surgery
Additional Departments
General Internal Medicine
PMID
DOI
10.1111/jocs.12312